Tweetable abstract Herpes zoster (HZ) is a vaccine-preventable disease, but the role of the vaccine in cancer patients during immunotherapy (ICIs) is still unknown. The clinical and economic consequences of HZ and the increased use of ICIs require a greater awareness by the oncologist.
Keywords: HZ; Herpes zoster; PD-L1; RZV vaccine; T-cell response; cancer; immune checkpoint inhibitors; immunotherapy; prevention; viral reactivation.